An Open-Label, One-Sequence, Two-Part Drug-Drug Interaction Study in Healthy Volunteers to Assess the CYP1A2 and CYP3A4 Perpetrator Interaction Potential and CYP1A2 Victim Potential of TEV-56286 (anle138b)
Latest Information Update: 27 Mar 2023
At a glance
- Drugs Emrusolmin (Primary) ; Fluvoxamine (Primary) ; Caffeine; Midazolam
- Indications Multiple system atrophy; Parkinson's disease
- Focus Pharmacokinetics
- Sponsors Modag
Most Recent Events
- 21 Mar 2023 Status changed from active, no longer recruiting to completed.
- 27 Jan 2023 Planned End Date changed from 1 Dec 2022 to 1 Jan 2023.
- 27 Jan 2023 Planned primary completion date changed from 1 Dec 2022 to 1 Jan 2023.